X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs BIOCON LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA BIOCON LTD DISHMAN PHARMA/
BIOCON LTD
 
P/E (TTM) x 25.1 36.6 68.6% View Chart
P/BV x 3.3 4.9 68.8% View Chart
Dividend Yield % 0.7 1.5 43.7%  

Financials

 DISHMAN PHARMA   BIOCON LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
BIOCON LTD
Mar-16
DISHMAN PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs374496 75.5%   
Low Rs129397 32.5%   
Sales per share (Unadj.) Rs197.8174.3 113.5%  
Earnings per share (Unadj.) Rs21.244.8 47.3%  
Cash flow per share (Unadj.) Rs34.756.9 61.0%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.81.1 70.9%  
Book value per share (Unadj.) Rs179.9202.8 88.7%  
Shares outstanding (eoy) m80.69200.00 40.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.6 49.7%   
Avg P/E ratio x11.910.0 119.2%  
P/CF ratio (eoy) x7.27.8 92.5%  
Price / Book Value ratio x1.42.2 63.6%  
Dividend payout %9.411.2 84.5%   
Avg Mkt Cap Rs m20,30689,220 22.8%   
No. of employees `0000.84.4 18.8%   
Total wages/salary Rs m5,3556,363 84.2%   
Avg. sales/employee Rs Th19,252.77,894.5 243.9%   
Avg. wages/employee Rs Th6,459.51,441.2 448.2%   
Avg. net profit/employee Rs Th2,064.12,029.7 101.7%   
INCOME DATA
Net Sales Rs m15,96134,854 45.8%  
Other income Rs m265845 31.4%   
Total revenues Rs m16,22635,699 45.5%   
Gross profit Rs m4,1038,200 50.0%  
Depreciation Rs m1,0912,423 45.0%   
Interest Rs m944102 925.9%   
Profit before tax Rs m2,3346,520 35.8%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m6242,569 24.3%   
Profit after tax Rs m1,7118,961 19.1%  
Gross profit margin %25.723.5 109.3%  
Effective tax rate %26.739.4 67.8%   
Net profit margin %10.725.7 41.7%  
BALANCE SHEET DATA
Current assets Rs m11,01839,932 27.6%   
Current liabilities Rs m9,51716,276 58.5%   
Net working cap to sales %9.467.9 13.9%  
Current ratio x1.22.5 47.2%  
Inventory Days Days11054 206.3%  
Debtors Days Days3586 40.4%  
Net fixed assets Rs m16,30439,101 41.7%   
Share capital Rs m1611,000 16.1%   
"Free" reserves Rs m12,90738,591 33.4%   
Net worth Rs m14,51640,556 35.8%   
Long term debt Rs m4,18920,724 20.2%   
Total assets Rs m29,80584,816 35.1%  
Interest coverage x3.564.9 5.3%   
Debt to equity ratio x0.30.5 56.5%  
Sales to assets ratio x0.50.4 130.3%   
Return on assets %8.910.7 83.4%  
Return on equity %11.822.1 53.4%  
Return on capital %17.519.0 92.4%  
Exports to sales %24.830.7 80.6%   
Imports to sales %3.720.4 18.3%   
Exports (fob) Rs m3,95610,717 36.9%   
Imports (cif) Rs m5967,105 8.4%   
Fx inflow Rs m4,95211,789 42.0%   
Fx outflow Rs m6978,393 8.3%   
Net fx Rs m4,2553,396 125.3%   
CASH FLOW
From Operations Rs m2,7865,264 52.9%  
From Investments Rs m-1,529-9,540 16.0%  
From Financial Activity Rs m-94110,867 -8.7%  
Net Cashflow Rs m3166,591 4.8%  

Share Holding

Indian Promoters % 61.4 40.4 152.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 3.7 8.4 44.0%  
FIIs % 12.7 10.7 118.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 19.9 111.1%  
Shareholders   46,261 109,995 42.1%  
Pledged promoter(s) holding % 35.8 0.0 89,400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  ALEMBIC LTD  

Compare DISHMAN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Energy Stocks Witness Buying(11:30 am)

After opening the day in green, Share markets in India witnessed volatile trading activity and are presently trading marginally above the dotted line.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS